Management of the cutaneous side effects of therapeutic epidermal growth factor receptor inhibition

Onkologie

Volumn 33, Issue 8-9, 2010, Pages 470-479

  Reck, Martin ^a   Gutzmer, Ralf ^b  

^a KRANKENHAUS GROSSHANSDORF   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Epidermal growth factor receptor; Erlotinib; Rash; Side effects, cutaneous; Tyrosine kinase inhibitor

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; BATRAFEN CREME; BEVACIZUMAB; BIOLOGICAL MARKER; CALCINEURIN INHIBITOR; CARBOPLATIN; CETIRIZINE; CETUXIMAB; CICLOPIROXOLAMINE; CISPLATIN; CORTICOSTEROID; DERMATOP CREME; DOXYCYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ERYTHROMYCIN; FLUCLOXACILLIN; GEFITINIB; GEMCITABINE; HYDROXYZINE; IMMUNOMODULATING AGENT; METRONIDAZOLE; MINOCYCLINE; NAVELBINE; PACLITAXEL; PARACETAMOL; PREDNICARBATE; RETINOID; STEROID; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACNE; ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL PROTOCOL; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; ECZEMA; HAIR DISCOLORATION; HAIR DISEASE; HEAD AND NECK CARCINOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HISTOPATHOLOGY; HUMAN; INCIDENCE; KERATINOCYTE; LOW DRUG DOSE; LUNG CANCER; LUNG NON SMALL CELL CANCER; MORNING DOSAGE; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; PANCREAS CANCER; PAPULOPUSTULAR ERUPTION; PARONYCHIA; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PERIUNGUAL INFLAMMATION; PUSTULE; QUALITY OF LIFE; RASH; REVIEW; SEBORRHEIC DERMATITIS; SKIN INFLAMMATION; SKIN PAIN; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; XEROSIS;

DERMATOLOGIC AGENTS; DRUG ERUPTIONS; HUMANS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 77956633076     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000317132     Document Type: Review

References (58)

1. Pastore S, Mascia F, Mariani V, Girolomoni G: The epidermal growth factor receptor system in skin repair and inflammation. J Invest Dermatol 2008;128:1365-1374.
2. Schneider MR, Werner S, Paus R, Wolf E: Beyond wavy hairs: the epidermal growth factor receptor and its ligands in skin biology and pathology. Am J Pathol 2008;173:14-24.
3. Lynch TJ, Jr, Kim ES, Eaby B, Garey J, West DP, Lacouture ME: Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 2007;12:610-621.
4. Pérez-Soler R, Saltz L: Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 2005;23:5235-5246.
5. Gridelli C, Maione P, Amoroso D, Baldari M, Bearz A, Bettoli V, Cammilluzzi E, Crin? L, De Marinis F, Di Pietro FA, Grossi F, Innocenzi D, Micali G, Piantedosi FV, Scartozzi M: Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: results of an Experts Panel Meeting. Crit Rev Oncol Hematol 2008;66:155-162.
6. Lacouture M, Cotliar J, Mitchell E: Clinical management of EGFRI dermatologic toxicities: US perspective. Oncology 2007;21(suppl 5):17-21.
7. Lacouture M, Melosky BL: Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective. Skin Therapy Lett 2007;12:1-5.
8. Herbst R, LoRusso P, Purdom M, Ward D: Dermatologic side effects associated with gefitinib therapy: clinical experience and management. Clin Lung Cancer 2003;4:366-369.
9. Pérez-Soler R, Delord JP, Halpern A, Kelly K, Krueger J, Sureda BM, von Pawel J, Temel J, Siena S, Soulières D, Saltz L, Leyden J: HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 2005;10:345-356.
10. Segaert S, Van Cutsem E: Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005;16:1425-1433.
11. Shepherd FA, Rodrigues PJ, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara P, Seymour L; National Cancer Institute of Canada Clinical Trials Group: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132. (Pubitemid 41058344)
12. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W; National Cancer Institute of Canada Clinical Trials Group: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-1966.
13. Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, De Rosa F, Milanowski J, Karnicka-Mlodkowski H, Pesek M, Serwatowski P, Ramlau R, Janaskova T, Vansteenkiste J, Strausz J, Manikhas GM, Von Pawel J: Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva lung cancer investigation trial. J Clin Oncol 2007;25:1545-1552.
14. Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P, Li X, Ramies D, Johnson DH, Miller VA; TRIBUTE Investigator Group: TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892-5899.
15. Reck M, Mali P, Arrieta O, Gottfried M, Van Meerbeeck J: Global efficacy and safety results from the TRUST study of erlotinib monotherapy in > 7000 patients (pts) with non-small cell lung cancer (NSCLC). Ann Oncol 2008;19(suppl 8):viii100, abstr 262P.
16. Van Cutsem E, Vervenne W, Bennouna J, Humblet Y, Gill S, Van Laethem JL, Verslype C, Scheithauer W, Shang A, Cosaert J, Moore MJ: Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009;27:2231-2237.
17. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V, Carroll K: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527-1537.
18. Kim E, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, Li LY, Watkins CL, Sellers MV, Lowe ES, Sun Y, Liao ML, Osterlind K, Reck M, Armour AA, Shepherd FA, Lippman SM, Douillard JY: Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008;372:1809-1818.
19. Giaccone G, Herbst R, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, Von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs JS, Averbuch SD, Wolf MK, Rennie P, Fandi A, Johnson DH: Gefitinib in combination with gemcitabine and cisplatin in advanced non-smallcell lung cancer: a phase III trial -INTACT 1. J Clin Oncol 2004;22:777-784. (Pubitemid 41103588)
20. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A, Johnson DH: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial -INTACT 2. J Clin Oncol 2004;22:785-794. (Pubitemid 41103589)
21. Van Cutsem E, Köhne C-H, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D?Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-1417.
22. Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Yu C-T, Ganul V, Roh J-K, Bajetta E, O?Byrne K, de Marinis F, Eberhardt W, Goddemeier T, Emig M, Gatzemeier U: Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009;373:1525-1531.
23. Saltz L, Kies M, Abbruzzese JL, Azarnia N, Needle M: The presence and intensity of the cetuximabinduced acne-like rash predicts increased survival in studies across multiple malignancies. Proc Am Soc Clin Oncol 2003;22:204, abstr 817.
24. Gridelli C, Bareschino MA, Schettino C Rossi A, Maione P, Ciardiello F: Erlotinib in non-small cell lung cancer treatment: current status and future development. Oncologist 2007;12:840-849.
25. Wacker B, Nagrani T, Weinberg J, Witt K, Clark G, Cagnoni PJ: Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007;13:3913-3921.
26. Jackman DM, Yeap BY, Lindeman NI, Fidias P, Rabin MS, Temel J, Skarin AT, Meyerson M, Holmes AJ, Borras AM, Freidlin B, Ostler PA, Lucca J, Lynch TJ, Johnson BE, J?nne PA: Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 2007;25:760-766.
27. Pérez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabárbara P, Bonomi P: Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004;22:3238-3247.
28. Soulières D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL: Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004;22:77-85.
29. Smit M, Reck M, Krzakowski M, Gridelli C, Curescu S, Berzinec P, Barata F, McDermott R, Jovanovic D, Magyar P: Erlotinib in patients with advanced non-small-cell lung cancer (NSCLC): interim results from the European subpopulation of the open-label TRUST study. Eur J Can Suppl 2007;5:359, abstr 6510.
30. Verslype C, Vervenne WL, Bennouna J, Humblet Y, Cosaert J, Van Cutsem E: Rash as a marker for the efficacy of gemcitabine plus erlotinib-based therapy in pancreatic cancer: Results from the AViTA study. J Clin Oncol 2009;27(suppl):abstr 4532.
31. Orditura M, De Vita F, Galizia G, Lieto E, Vecchione L, Vitiello F, Martinelli E, Ciardiello F: Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis. Oncol Rep 2009; 21:1023-1028.
32. Mohamed M, Ramalingam S, Lin Y, Gooding WE, Cronin W, Eckardt JR, Belani CP: Skin rash and good performance status (PS) predict improved survival with gefitinib for patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2004;22(suppl 14):637, abstr 7097.
33. Cohen EE, Rosen F, Stadler WM, Recant W, Stenson K, Huo D, Vokes EE: Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003;21:1980-1987.
34. Pérez-Soler R: Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer. Clin Lung Cancer 2006;8(suppl 1):S7-S14.
35. Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, Wikstrand CJ, Van Duyn LB, Dancey JE, McLendon RE, Kao JC, Stenzel TT, Ahmed Rasheed BK, Tourt-Uhlig SE, Herndon JE 2nd, Vredenburgh JJ, Sampson JH, Friedman AH, Bigner DD, Friedman HS: Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004;22: 133-142.
36. West HL, Franklin WA, McCoy J, Gumerlock PH, Vance R, Lau DH, Chansky K, Crowley JJ, Gandara DR: Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126. J Clin Oncol 2006;24:1807-1813.
37. Fujiwara Y, Kiura K, Toyooka S, Hotta K, Tabata M, Takigawa N, Soh J, Tanimoto Y, Kanehiro A, Kato K, Date H, Tanimoto M: Elevated serum level of sialylated glycoprotein KL-6 predicts a poor prognosis in patients with non-small cell lung cancer treated with gefitinib. Lung Cancer 2008; 59:99-103.
38. Rudin CM, Liu W, Desai A, Karrison T, Jiang X, Janisch L, Das S, Ramirez J, Poonkuzhali B, Schuetz E, Fackenthal DL, Chen P, Armstrong DK, Brahmer JR, Fleming GF, Vokes EE, Carducci MA, Ratain MJ: Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol 2008;26:1119-1127.
39. Lacouture ME: Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006;6:803-812.
40. Melosky B, Burkes R, Rayson D, Alcindor T, Shear N, Lacouture M: Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations. Curr Oncol 2009;16:16-26.
41. Gutzmer R, Werfel T, Kapp A, Elsner J: Cutaneous side effects of EGF-receptor inhibition and their management. J Hautarzt 2006;57:509-513.
42. Hassel JC, Kripp M, Al-Batran S, Hofheinz RD: Treatment of epidermal growth factor receptor antagonist-induced skin rash: results of a survey among German oncologists. Onkologie 2010;33:94-98.
43. Zoller A, Sch?d S, Gross G: Erlotinib-associated skin reactions -case report and proposal for classification. Br J Dermatol 2006;155:1293-1307.
44. Wollenberg A, Moosmann N, Klein E, Katzer K: A tool for scoring of acneiform skin eruptions induced by EGF receptor inhibition. Exp Dermatol 2008;17:790-792.
45. Jatoi A, Rowland K, Sloan JA, Gross HM, Fishkin PA, Kahanic SP, Novotny PJ, Schaefer PL, Johnson DB, Tschetter LK, Loprinzi CL: Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-con trolled trial from the North Central Cancer Treatment Group (N03CB). Cancer 2008;113:847-853.
46. Shah NT, Kris MG, Pao W, Tyson LB, Pizzo BM, Heinemann MH, Ben-Porat L, Sachs DL, Heelan RT, Miller VA: Practical management of patients with non-small-cell lung cancer treated with gefitinib. J Clin Oncol 2005;23:165-174.
47. Lacouture ME, Basti S, Patel J, Benson A, III: The SERIES clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors. J Support Oncol 2006;4:236-238.
48. Wollenberg A, Moosmann N, Kroth J, Heinemann V, Klein E: Therapie schwerer akneiformer Cetuximab-Exantheme mit oralem Retinoid, topischem Antibiotikum und Steroidexternum. Hautarzt 2007;58:615-618.
49. Hu JC, Sadeghi P, Pinter-Brown LC, Yashar S, Chiu MW: Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol 2007;56:317-326.
50. Busam KJ, Capodieci P, Motzer R, Kiehn T, Phelan D, Halpern AC: Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001;144:1169-1176.
51. De Noronha E, Menezez N, Lima R, Moreira A, Varela P, Barroso A, Baptista A, Parente B: Description and management of cutaneous side effects during erlotinib and cetuximab treatment in lung and colorectal cancer patients: A prospective and descriptive study of 19 patients. Eur J Dermatol 2009;19:1-4.
52. Kimyai-Asadi A, Jih MH: Follicular toxic effects of chimeric anti-epidermal growth factor receptor antibody cetuximab used to treat human solid tumors. Arch Dermatol 2002;138:129-131.
53. Gutzmer R, Werfel T, Mao R, Kapp A, Elsner J: Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy. Br J Dermatol 2005;153:849-851.
54. Bernier J, Bonner J, Vermorken JB, Bensadoun RJ, Dummer R, Giralt J, Kornek G, Hartley A, Mesia R, Robert C, Segaert S, Ang KK: Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol 2008;19:142-149.
55. Budach W, Bölke E, Homey B: Severe cutaneous reaction during radiation therapy with concurrent cetuximab. N Engl J Med 2007;357:514-515.
56. Scope A, Agero AL, Dusza SW, Myskowski PL, Lieb JA, Saltz L, Kemeny NE, Halpern AC: Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximabassociated acne-like eruption. J Clin Oncol 2007;25:5390-5396.
57. Galimont-Collen AFS, Vos LE, Lavrijsen AP, Ouwerkerk J, Gelderblom H: Classification and management of skin, hair, nail and mucosal sideeffects of epidermal growth factor receptor (EGFR) inhibitors. Eur J Cancer 2007;43:845-851.
58. Basti S: Ocular toxicities of epidermal growth factor receptor inhibitors and their management. Cancer Nurs 2007;30(suppl 1):S10-S16.